Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

Alan Pehrson, Steven C. Leiser, Maria Gulinello, Elena Dale, Yan Li, Jessica A. Waller, Connie Sanchez

Research output: Contribution to journalArticleResearchpeer-review

52 Citations (Scopus)

Abstract

Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography.

Original languageEnglish
Pages (from-to)19-31
Number of pages13
JournalEuropean Journal of Pharmacology
Volume753
DOIs
StatePublished - 15 Apr 2015

Fingerprint

Major Depressive Disorder
Serotonin Uptake Inhibitors
Antidepressive Agents
Cognition
Electroencephalography
Electrophysiology
Neurogenesis
Microdialysis
Therapeutics
Mood Disorders
Rodentia
Depression
Cognitive Dysfunction
Serotonin and Noradrenaline Reuptake Inhibitors
vortioxetine

Keywords

  • Cognitive function
  • Electrophysiology
  • Lu AA21004
  • Major depressive disorder
  • Receptor occupancy
  • Vortioxetine

Cite this

@article{82efd10432524c54a0f826fc68012d02,
title = "Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine",
abstract = "Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography.",
keywords = "Cognitive function, Electrophysiology, Lu AA21004, Major depressive disorder, Receptor occupancy, Vortioxetine",
author = "Alan Pehrson and Leiser, {Steven C.} and Maria Gulinello and Elena Dale and Yan Li and Waller, {Jessica A.} and Connie Sanchez",
year = "2015",
month = "4",
day = "15",
doi = "10.1016/j.ejphar.2014.07.044",
language = "English",
volume = "753",
pages = "19--31",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. / Pehrson, Alan; Leiser, Steven C.; Gulinello, Maria; Dale, Elena; Li, Yan; Waller, Jessica A.; Sanchez, Connie.

In: European Journal of Pharmacology, Vol. 753, 15.04.2015, p. 19-31.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

AU - Pehrson, Alan

AU - Leiser, Steven C.

AU - Gulinello, Maria

AU - Dale, Elena

AU - Li, Yan

AU - Waller, Jessica A.

AU - Sanchez, Connie

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography.

AB - Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography.

KW - Cognitive function

KW - Electrophysiology

KW - Lu AA21004

KW - Major depressive disorder

KW - Receptor occupancy

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=84925584026&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.07.044

DO - 10.1016/j.ejphar.2014.07.044

M3 - Article

VL - 753

SP - 19

EP - 31

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -